<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513342</url>
  </required_header>
  <id_info>
    <org_study_id>JSLCG-001</org_study_id>
    <nct_id>NCT02513342</nct_id>
  </id_info>
  <brief_title>Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma</brief_title>
  <official_title>Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients：a Randomized Controlled,Open, Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing NingQi Medicine Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing NingQi Medicine Science and Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection
      pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance
      treatment., and explore the predicted biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to month 36</time_frame>
    <description>FS is a tumor progression or death time of a patient who has an objective record on the date of enrollment. PFS calculation end if the patient was lost, unknow death , or other anti tumor therapy was used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall remission rate(ORR)</measure>
    <time_frame>change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate （DCR）</measure>
    <time_frame>change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Advanced Lung Squamous Carcinoma</condition>
  <arm_group>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel+Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Endostar 30mg continuous intravenous injection pump,d1-d7；</description>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>d4 Docetaxel，75（mg/m2），iv；</description>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
    <arm_group_label>Docetaxel+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>d4，cisplatin，75（mg/m2），iv；</description>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
    <arm_group_label>Docetaxel+Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cytological and histological confirmation（Do not accept single sputum cytology in the
             diagnosis of patients） in patients diagnosed of lung squamous carcinoma;

          2. According to a new IASLC2009 lung cancer TNM stages judged stage IIIB or IV non-small
             cell lung cancer.

          3. Must have at least one evaluated lesion,according to the RRECIST version 1.1 standard
             (the longest diameter on spiral CT at least 10 mm,the longest diameter on plain CT at
             least 20 mm);

          4. Male or female, age between 18 and 75 years old ;

          5. ECOG PS 0~1；

          6. Expected survival period ≥ 3 months or more

          7. Enough blood function: absolute neutrophil count (ANC)≥2 x 109 / L and the platelet
             count≥ 100 x 109 / L and hemoglobin ≥9 g/dL;

          8. Enough liver function: total bilirubin acuities≤the upper limit of normal (ULN); AST
             and ALT acuities ≤2.5 times of the upper limit of normal (ULN); Alkaline phosphatase
             ≤5 times of the upper limit of normal(ULN);

          9. Enough renal function：serum creatinine ≤the limit of normal(ULN) or calculated
             creatinine clearance≥60 mL/min.

         10. The electrocardiogram (ecg) basicaly normal,the body had no to heal wounds

         11. No previous anti-tumor drug therapy, or only received for non metastatic tumor of
             adjuvant or neoadjuvant chemotherapy, but has ended more than six months before the
             study start.

         12. Patients had surgery before,but have more than 4 weeks before the study star, and the
             patient has recovered;

         13. Women with cmpleted uterus before intact in the group within 28 days must have a
             negative pregnancy test results (unles amenorrhea for 24 months). If the pregnancy
             test from the first time for more than 7 days,the patients need for urine pregnancy
             test(within 7 days before the first delivery).

         14. Prior to biological agents, especially e. coli genetically engineered products without
             severe allergic reactions;

         15. Sign the informed consent.

        Exclusion Criteria:

          1. Pregnancy, nursing mothers, or female patients with fertility but no contraception.

          2. Existing serious acute infection, and can not be controlled; Or with fester sex and
             chronic infection,or wound in delay;

          3. Original serious heart disease, including: congestive heart failure, uncontroled high
             risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart
             disease, and resistant hypertension;

          4. With uncontroled nerve, mental illness or mental disorders, compliance is poor, can't
             cooperate and response to treatment; Uncontroled primary brain tumors or CNS
             metastases illness, with obvious symptoms in cranial hypertension or nerve spirit;

          5. With a bleeding tendency

          6. Researchers believe that patients should not participate in this test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yin Qingfeng, manager</last_name>
    <phone>0086-02585632992</phone>
    <email>y_qingfeng@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhou Xiaolei, sponsor</last_name>
    <phone>0086-02585566666</phone>
    <email>zhouxiaolei@simcere.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Qingfeng, Manager</last_name>
      <phone>0086013912903257</phone>
      <email>y_qingfeng@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhou Xiaolei, Manager</last_name>
      <phone>0086013776639377</phone>
      <email>zhouxiaolei@simcere.com</email>
    </contact_backup>
    <investigator>
      <last_name>Song Yong, director</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of soochow university</name>
      <address>
        <city>Soochow</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Qingfeng, mananger</last_name>
      <phone>08613912903257</phone>
      <email>y_qingfeng@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhou Xiaolei, mananger</last_name>
      <phone>08613776639377</phone>
      <email>zhouxiaolei@simcere.com</email>
    </contact_backup>
    <investigator>
      <last_name>Huang Jianan, director</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endostar,Advanced lung squamous carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

